Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 3/2000

01-08-2000

Phase II Trial of Aminocamptothecin (9-AC/DMA) in Patients with Advanced Squamous Cell Head and Neck Cancer

Authors: Thomas Lad, Fred Rosen, David Sciortino, Bruce Brockstein, J. Philip Keubler, Rose Arietta, Everett Vokes

Published in: Investigational New Drugs | Issue 3/2000

Login to get access
Metadata
Title
Phase II Trial of Aminocamptothecin (9-AC/DMA) in Patients with Advanced Squamous Cell Head and Neck Cancer
Authors
Thomas Lad
Fred Rosen
David Sciortino
Bruce Brockstein
J. Philip Keubler
Rose Arietta
Everett Vokes
Publication date
01-08-2000
Publisher
Kluwer Academic Publishers
Published in
Investigational New Drugs / Issue 3/2000
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1023/A:1006481924287

Other articles of this Issue 3/2000

Investigational New Drugs 3/2000 Go to the issue

OriginalPaper

Phase II Study of Intravenous Doxil® in Malignant Pleural Mesothelioma

OriginalPaper

The Oral Route for the Administration of Cytotoxic Drugs: Strategies to Increase the Efficiency and Consistency of Drug Delivery

OriginalPaper

A North Central Cancer Treatment Group Phase II Trial of Topotecan in Relapsed Gliomas

OriginalPaper

Development of Multidrug-Resistance Convertors: Sense or Nonsense?

OriginalPaper

Phase II Trial of Liposomal Doxorubicin (Doxil®) in Advanced Soft Tissue Sarcomas

OriginalPaper

A Randomized Trial Comparing the Nephrotoxicity of Cisplatin/Ifosfamide-Based Combination Chemotherapy with or without Amifostine in Patients with Solid Tumors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits